Full Press Release Details
Solid Biosciences Granted FDA Orphan Drug Designation Duchenne.
SLDB
Solid Biosciences Granted FDA Orphan Drug Designation Duchenne
Key Takeaway: Solid Biosciences Granted FDA Orphan Drug Designation Duchenne
Price reaction · baseline $7.71 (2024-01-12 close) · hit after-hours · clean, no other SLDB news in the window
day 0 close
+3.8%
day 1
+4.5%
day 3
+5.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
7.4%
average across 7 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
carmustine
Phase 3 · Lymphoma